As a medical school professor, I remind students: weight-loss drugs aren't just "appetite meds." They're metabolic signaling.

A new proof-of-concept RCT in The Lancet (EClinicalMedicine) tested dapiglutide—a dual GLP-1 + GLP-2 agonist—once weekly for 12 weeks in adults with obesity (n=54).

Results (relative bodyweight change):
• Placebo: −2.2%
• Dapiglutide 6 mg: −4.3%
(Estimated treatm...
#obesity #GLP1 #metabolichealth #insulinresistance #cardiometabolic
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00048-9/fulltext